Latest Industry Projects

AstraZeneca selects location for new global R&D centre and corporate headquarters in Cambridge, UK.

projects

Move brings AstraZeneca’s small molecule and MedImmune’s biologics research and development together at purpose-built facility on Cambridge Biomedical Campus AstraZeneca today announced that its new UK-based global research and development centre and corporate headquarters will be located at the Cambridge Biomedical Campus on the southern outskirts of the city. By 2016, the new site will house a highly-skilled workforce of approximately 2,000. As announced in March 2013, the investment in a £330 million facility in Cambridge is part of the company’s move to create strategic global R&D centres in the UK, US and Sweden to improve pipeline productivity and to establish AstraZeneca as a global leader in biopharmaceutical innovation. The purpose-built site in Cambridge will bring together AstraZeneca’s small molecule and biologics research and development activity, opening up opportunities to exploit the promise of small and large molecule combinations. The Cambridge Biomedical Campus will be the new UK home for biologics research and protein engineering carried out by MedImmune, AstraZeneca’s biologics arm. MedImmune already employs around 500 people at Granta Park, to the south east of the city. The new site will also become the company’s largest centre for oncology research as well as hosting scientists focused on cardiovascular and metabolic diseases, respiratory, inflammation and autoimmune diseases and conditions of the central nervous system. Work carried out in Cambridge will include medicinal chemistry and high-throughput screening and the facility will accommodate a number of AstraZeneca’s pre-clinical research capabilities. Other global functions will join the research and development teams at the new facility and Cambridge will become AstraZeneca’s corporate headquarters. The Cambridge Biomedical Campus site is a growing and thriving hub for world-renowned biomedical activity. It is home to leading research, academic and healthcare organizations including the University Of Cambridge School Of Clinical Medicine, Addenbrooke’s Hospital, the Medical Research Council (MRC) Laboratory of Molecular Biology, the Wellcome Trust-MRC Institute of Metabolic Science and the Cancer Research UK Cambridge Institute. The AstraZeneca facility will occupy approximately 11 acres of the 70 acre campus, which benefits from a central Cambridge location and strong infrastructure links. http://www.astrazeneca.com/Media/Press-releases/Article/20130618--astrazeneca-selects-Cambridge-for-global-research-centre-corproate-headquarters Project Name AstraZeneca announces global research and development centre Location United Kingdom Commence 2013 Completion -NA- Estimated Investment GBP 330 million Capacity -NA- Key Players AstraZeneca

Other Projects